Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

PI: Frank A. Vicini


  • Lung Cancer


Michigan: Maria Pappas (248) 553-0606


  • Lung cancer

Primary Objective:
To compare progression free survival (PFS) and overall survival (OS) for patients with limited stage small cell lung cancer (LS-SCLC) treated with chemoradiation +/- atezolizumab.

Patient Population:
Patients with pathologically (histologically or cytologically) proven diagnosis of limited stage (Tx, T1-T4, N0-3, M0) small cell lung cancer (LS-SCLC) who have received one pre-registration cycle of platinum/etoposide chemotherapy prior to study entry.